Paraguay Wrong Classification Penalties: NSO Invalidation and Market Withdrawal under Article 7

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

  1. Article 7 states expressly: where the classification declaration is incorrect or does not correspond to the classification rules, the NSO already issued becomes invalid. The rule operates on the issued document itself, so the defect is not treated as a curable formality but as a ground that unwinds the authorization.
  2. The consequences proceed in three escalating steps: first, declaration of the invalidity of the NSO; second, an order requiring the registration holder to withdraw the device from the market (retiro del mercado); third, in the event of repetition, the temporary or permanent closure of the establishment (establecimiento) following an administrative proceeding (previo sumario administrativo).
  3. An additional hard rule applies: once the NSO has been issued, no application may be made to change the declared Class I status. There is no correction channel after issuance, which means the classification judgment carries its full consequences permanently unless a fresh application is made.
  4. Where the classification declaration for a Class II, III or IV device is rejected, the rejection must state its reasons and the application must be cancelled in the system, and the application must be resubmitted with the fee paid again (Article 4). The higher-class pathways therefore carry a restart cost rather than an invalidity sanction, but the fee is lost all the same.

2. Legal basis

RegulationReferenceDateProvisions
Resolution on market authorization requirements for medical devicesResolución DINAVISA N° 226/20242024-08-27; Article 36: entered into force 2024-09-16Articles 4 and 7
Operational instructions and guide for submitting applicationsInstructivo ITR–DGRS-002, Versión 022024-09-09Page 7, section A TENER EN CUENTA

The warning is not buried in an annex: the operational instructions reproduce it on page 7 under the heading A TENER EN CUENTA, at the very point where the NSO process flow is described, so the applicant encounters the consequences of a wrong classification at the same moment as the procedure itself. The combination of the invalidity rule in Article 7, the resubmission and fee rule in Article 4, and the highlighting in the instructions makes classification correctness a first-order compliance duty under the Paraguayan framework rather than a technical afterthought.

On the higher-class side, the mechanics of Article 4 are different but not costless. Where the classification declaration of a Class II, III or IV device is rejected, the rejection must state its reasons, the application must be cancelled in the system, and a new application must be filed with the corresponding fee paid again. The rule preserves the possibility of entering the market under the correct class, but every element of the first submission, including the fee and the elapsed preparation time, is consumed by the restart. For Class I, no such restart exists: the combination of the invalidity rule, the withdrawal order and the closure clause in Article 7, together with the absence of a reclassification channel, makes the pre-submission classification review the only effective control point in the entire lifecycle.

3. Expert insights

Insight one: this rule raises the cost of a classification error from correction to total reset. In most jurisdictions, a classification error can be remedied by submitting supplementary documentation or moving to a higher pathway. For Class I in Paraguay, the rule instead establishes invalidity plus market withdrawal. This is not a procedural defect to be cured: it zeroes out the entire market access, and the costs already invested in translation, certification and local representation are entirely sunk. The commercial exposure extends beyond regulatory costs to supply commitments, because every unit already distributed becomes part of a withdrawal order.

Insight two: the repetition clause targets the establishment, not the product. The third consequence of Article 7 addresses the temporary or permanent closure of the establishment, and only after an administrative proceeding has taken place. For structures in which a local importer holds the registration, the risk lands directly on the operating license of the partner. This makes distributors extremely conservative in subsequent cooperation, and they may refuse to handle borderline products altogether, which in practice narrows the market access options for any portfolio containing classification-sensitive items.

Insight three: the no-reclassification rule combined with the 10-year validity period creates a long-cycle lock-in. The NSO is valid for 10 years (Article 10). A product wrongly classified as Class I, if not detected, will exist in a non-compliant state for the full 10 years; once detected, all prior sales are exposed to retroactive scrutiny. This is a classic structure of deferred risk, in which the heaviest consequences arrive years after the original decision, long after the people who made it have moved on, which is why portfolio-level retrospective reviews matter more in Paraguay than in correction-friendly jurisdictions.

4. Practical recommendations

  1. For borderline products, complete a three-level review before submission: self-assessment by the technical director, cross-market comparison review against how comparable products are classified elsewhere, and, where necessary, a pre-submission consultation with DINAVISA to resolve the doubt before money and time are committed.
  2. The classification rationale document must map to the rules of Annex I item by item, preserving the reasoning process rather than only the conclusion, so that an inspector can follow the path from rule to result without needing to reconstruct it.
  3. Include notification and cooperation clauses on classification risk in distribution agreements, clearly allocating costs and responsibilities in a market withdrawal scenario, covering logistics, refund and destruction duties.
  4. For products already holding a Class I NSO, conduct a retrospective classification review across the portfolio; where the classification is in doubt, evaluate the timing and cost of proactively reapplying under the correct pathway before the issue is discovered by the authority.

5. Verification checklist

  • □ Three-level classification review completed for borderline products before submission
  • □ Classification rationale document preserves the reasoning process (not only the conclusion) against Annex I
  • □ Confirmed that no correction channel exists for the classification after NSO issuance
  • □ Distribution agreements contain cost and liability clauses for market withdrawal scenarios
  • □ Retrospective classification review completed for the existing Class I NSO portfolio, with findings documented

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support for manufacturers, importers and authorized representatives in Paraguay, covering classification review, risk assessment and corrective strategy under Article 7 of Resolución DINAVISA N° 226/2024. Contact: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail